Company Overview and News

 
Spark expects annual earnings to fall

20h nzherald.co.nz
Spark New Zealand expects annual earnings to fall by as much as 2.5 per cent this year as it brings forward restructuring costs and accelerates its 'Quantum Programme' to transform the country's biggest telecommunications company into the operator with the lowest costs.

 
Shares up as Comvita, A2 rebound from weakness, Steel & Tube keeps dropping

20h nzherald.co.nz
New Zealand shares gained as Comvita and A2 Milk Co recovered from selling, while Air New Zealand and Steel & Tube Holdings fell.

 
Honey products exporter Comvita leads sharemarket down

2018-05-21 nzherald.co.nz
New Zealand shares dropped, led lower by Comvita as its possible takeover failed, with A2 Milk continuing last week's losses and Kiwi Property Group dropping on its earnings.

 
Shares gain as Ryman posts record profit

2018-05-18 nzherald.co.nz
New Zealand shares rose as Goodman Property Trust's joint venture with GIC sold seven buildings in downtown Auckland, and as Ryman Healthcare chalked up another record profit. A2 Milk Co and Comvita fell.

 
Shares rise, led by A2 and Synlait

2018-05-17 nzherald.co.nz
New Zealand shares rose, led by A2 Milk Co and Synlait Milk while Pushpay fell after annual earnings met its guidance, disappointing some upbeat investors.

 
A2 tumbles, dragging down stock index

2018-05-16 nzherald.co.nz
New Zealand shares fell as A2 Milk Co disappointed investors with a market update, dragging down partner Synlait Milk.

 
Expert: A2 Milk could replace Fletcher Building in key sharemarket index

2018-05-13 nzherald.co.nz
Mark Lister, head of private wealth research at Craigs Investment Partners, said the announcement of Fletcher's place in the MSCI Index is due out today and we will know the result tomorrow.

 
Shares rise as investors second guess index changes; Fletcher gains

2018-05-08 nzherald.co.nz
New Zealand shares rose, joining a regional rally, as investors predict whether an upcoming MSCI index review will spur major activity next week. Fletcher Building, which could exit the index, gains, while new addition a2 Milk Co fell.

 
NZ shares mixed, A2 gains while Gentrack, Spark, bank stocks drop

2018-05-04 nzherald.co.nz
New Zealand shares were mixed, with A2 Milk pulling the index up while Gentrack Group, Spark New Zealand and banking stocks dropped.

 
Spark sells 50 pct stake in services infrastructure unit to Electra Group

2018-05-03 nzherald.co.nz
Spark New Zealand is selling half of its Connect 8 services infrastructure unit to electricity distributor Electra Group, in a deal which will see Connect 8 take full ownership of Electra's telecommunication's contractor Sky Communications.

 
NZ shares up as A2 leads index

2018-05-02 nzherald.co.nz
New Zealand shares gained, with Gentrack Group hitting a record and electricity companies Mercury New Zealand and Contact Energy gaining.

 
NZ shares up 1%, led by Fisher & Paykel, Kathmandu, Spark

2018-04-27 nzherald.co.nz
New Zealand shares gained, led by Fisher & Paykel Healthcare Corp and Kathmandu in broad-based buying.

 
NZ shares gain; Trade Me rises

2018-04-18 nzherald.co.nz
New Zealand shares gained in light trading as Fletcher Building's discounted rights issue and upcoming MSCI New Zealand index review weighed on investors' minds. Trade Me and Metlifecare increased while Comvita dropped.

 
Shares fall as investors weight up Fletcher rights issue

2018-04-17 nzherald.co.nz
New Zealand shares fell as investors weighed up the impact of Fletcher Building's deeply discounted rights issue soaking up demand from the broader market. Auckland International Airport and exporters A2 Milk Co and Comvita dropped.

1
Shares fall as global tensions keep investors on the sidelines

2018-04-16 nzherald.co.nz
New Zealand shares fell in relatively subdued trading, led by Ebos Group, Ryman Healthcare, Air New Zealand and Fletcher Building. Comvita fell after a profit warning while A2 Milk gained on news of a deal in South Korea.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...